Galectin Therapeutics (GALT)

• Market cap: $205M
• 1 day: 2.91%
• 5 days: -5.92%
• 1 month: 16.06%
• 3 months: -48.71%
• 6 months: -27.89%
• Year to date: -21.48%
• 1 year: 97.52%
• 5 years: 33.61%
• 10 years: 152.38%
• Sector: Healthcare
• Industry: Biotechnology

About: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Employees: 15